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Reversible tyrosine phosphorylation plays an important role in signaling 
pathways that are essential for regulating cellular growth, differentiation and metabolism. 
Moreover, several human diseases such as diabetes, obesity and cancers are 
associated with the deregulation of protein tyrosine phosphatases (PTPs). Several 
studies provide evidence that PTPs not only contribute to cellular differentiation, but 
over-expression of these molecules also leads to transformation of non-transfomed cells 
as well. Based on these results, designing specific PTP inhibitors may ultimately function 
as potential therapeutic agents to treat various diseases including cancer, diabetes, and 
autoimmune diseases. EphA2 is a receptor tyrosine kinase which is hypo-
phosphorylated and overexpressed in many metastatic cancers. The level of 
phosphorylation of EphA2 is controlled by the human cytoplasmic protein tyrosine 
phosphatase (HCPTP), which is also overexpressed in cancers. Two low molecular 
weight PTP isoenzymes, HCPTP-A and HCPTP-B, are generally expressed in humans. 
Interestingly, HCPTP-A and -B preferentially dephosphorylate different phosphotyrosine 
sites related to control of EphA2 activity and downstream signaling pathways. In addition, 
HCPTP-A and HCPTP-B have highly different activities towards substrates including 
pNPP and inhibitors. However, research to determine each characteristic of HCPTP-A 
and HCPTP-B, has not been done. Our research aims to shed light upon the key 
residues of HCPTP-A and HCPTP-B for substrate binding and activity through the use of 
site-directed mutagenesis. Because both EphA2 and HCPTP are related to cancer, 
revealing key residues that control the affinity of specific substrates to HCPTP-A and -B 
may yield an advance in understanding the biological roles of HCPTP as well as 








1.1. Human Cytoplasmic Protein Tyrosine Phosophatase  
 
Human cytoplasmic protein tyrosine phosphatase (HCPTP) was initially identified 
as an acid phosphatase from red blood cells (1).  The human ACP1 gene, located on the 
short arm of choromosome 2, includes 7 exons and 6 introns (2). Four isoforms of 
HCPTP arise from an alternative splicing of a primary transcript. Three mRNAs encode 
for HCPTP-A, -B, and -C in Figure 1.1 (3). HCPTP-A and HCPTP-B are active isoforms, 
resulting from mutually exclusive retention of exon 3f (in HCPTP-A) or exon 3s (in 
HCPTP-B) (4). However, HCPTP-C is an inactive protein, which has neither exon 3 nor 
exon 4 (5). The HCPTP-A and HCPTP-B show different electrophoretic mobility. While 
HCPTP-A electrophoretically migrates more slowly, HCPTP-B shows fast electrophoretic 
mobility (6). Moreover, they have different activity towards inhibitors and 
phosphotyrosine peptides (7). HCPTP-A has a higher activity towards phosphotyrosine, 
p-Nitrophenyl Phosphate (pNPP) and inhibitors, while HCPTP-B shows a lower 















Figure 1.1. Isoforms of HCPTP (3). Alternative splicing of the ACP1 pre-mRNA leads to 
HCPTP-A, HCPTP-B, and HCPTP-C. HCPTP-A and -B result from mutually exclusive 
retention of the third exon (3f in HCPTP-A), or the fourth exon (3s in HCPTP-B). HCPTP-
C is a catalytically inactive isoform (removal of both exon 3f and 3s).Image modified from  


















1.1.1. HCPTP Structure and Function 
 
The HCPTP-A and -B are soluble proteins with molecular mass of approximately 
18,000 Da. They consist of single polypeptide chains of 157 amino acids and have 
identical sequence including the PTPase consensus sequence CX5R which forms the 
active site P loop. The only different sequence between HCPTP-A and -B is an mRNA 
splice variant sequence containing amino acids 40 - 73 which forms the variable loop as 
shown in Figure 1.2 (8). The structure of HCPTP isoforms comprise a four-stranded 
central parallel β sheet and contain flanking α-helices on both sides which show two 
right-handed βαβ motifs as seen in Figure 1.3 (8). 
Despite HCPTP-A and -B showing the structurally similar active site including the 
CX5R, universal PTPase consensus sequence, they have different activity towards 
inhibitors and phosphotyrosine peptides (7). Moreover, HCPTP-A and -B preferentially 
dephosphorylate different phosphotyrosine sites related to control of EphA2 activity and 
downstream signaling pathways (9). By using a mass spectrometry-based assay, 
Balasubramaniam et al. showed the HCPTP-A and HCPTP-B have different 
dephosphorylation rates at the phosphotyrosine sites associated with control of EphA2 
activity (Figure 1.4). It was illustrated that tyrosine Y772 of the kinase domain is 
dephosphorylated about 6 times faster by HCPTP-A, while tyrosine Y960 of the SAM 
domain is dephosphorylated only by HCPTP-B. Balasubramaniam et al. demonstrated in 
Figure 1.5 the kinase domain tyrosine, Y772 is the preferred target for dephosphoylation 
by HCPTP-A and the SAM domain tyrosine, Y960 is a site for dephosphorylation only by 
HCPTP-B (9). 
Based on the preliminary study, three potential variable loop residues (49, 50, 
and 53) may influence the enzyme activity and substrate binding for HCPTP-A and -B in 
Figure 1.6 (7). Residue 49, which is Tyrosine (Tyr) in HCPTP-A and Tryptophan (Trp) in 
HCPTP-B, located above the active site forming the hydrophobic sandwich with residues 
Tyr-131 and -132, affects interaction of the ring portion of phosphotyrosine substrates. 
Residues 50 and 53 contribute to the difference of the variable loops charge distribution. 
Residue 50, Glutamic Acid (Glu) in HCPTP-A, contains a negatively charged side chain, 
whereas, residue 53, which is Arginine (Arg) in HCPTP-B, possesses a positively 
charged side chain. These two residues, 50 and 53, are important for the interaction of 





Figure 1.2. Sequence alignment of HCPTP-A and HCPTP-B (8). 
Secondary structure elements were shown under the sequences. Critical catalytic 
residues are highlighted in black. The PTPase consensus sequence CX5R (appears as 
sequence CLGNICRS) forms the active site P loop (black highlighting). The variable 
sequence between residues 40 and 73 forms the variable loop (gray highlighting). Image 













Figure 1.3. Ribbon diagrams of the fold of HCPTP-A (8). 
A) The active site P loop (in red) connecting the first β strand (β1) to the first turn of the 
helix, α1. B) The variable loop (in purple) includes β2, the loop connecting β2 and α2, 









Figure 1.4. Dephosphorylation rates of the two HCPTP variants toward EphA2 phospho-
peptides (9). SRM-MS analysis was used to determine the dephosphorylation rates of 
HCPTP-A (Left) and HCPTP-B (Right) against EphA2 phosphotyrosine peptides. 
Phosphorylation of sample at time 0 was adjusted to 100% and the percentage 
phophorylation was plotted relative to 0 minutes. Image modified from Balasubramaniam 

























Figure 1.5. Specificity of HCPTP-A and -B against EphA2 tyrosines (9). The unstructured 
loop is the juxtamembrane region with three phosphorylated tyrosines marked by purple 
circle. The kinase domain of EphA2 is drawn in orange followed by the SAM domain 
shown in red with tyrosine marked by purple circle. The kinase domain tyrosine is a 
preferred target for dephosphorylation by HCPTP-A. The tyrosine in the SAM domain is 
a target for dephosphorylation exclusively by HCPTP-B. Image modified from 














Figure 1.6. Electrostatic surface representation of HCPTP-A (left) and HCPTP-B (right) 
(7).  The entrance to the active site appears as a circular depression at the center of the 
molecule. The crevice leading into the active-site pocket from the lower right is supposed 
to be the peptide biding site. The most dramatic charge alteration on the surface is near 
the active site, due to changes in residues 50 and 53, which border the crevice. Glu-50 
in HCPTP-A contains a negatively charged side chain, whereas, Arg-53 in HCPTP-B 
possesses a positively charged side chain. Charge distributions are indicated by red 
(negative) and blue (positive). Image modified from Adam P. R. Zabell et al. 2005. Image 












1.1.2. HCPTP in Cancer and Diseases 
 
 EphA2 is a receptor tyrosine kinase which is hypo-phosphorylated and 
overexpressed in many metastatic cancers. The level of phosphorylation of EphA2 is 
regulated by the human cytoplasmic protein tyrosine phosphatase (HCPTP), which is 
also overexpressed in cancers as seen in Figure 1.7 (10). This indicates that HCPTP 
has oncogenic potential and seems to play an important role in metastatic transformation. 
Moreover, several PTPs have been associated with many diseases including 
obesity, autoimmune and infectious diseases. A mutated SHP-1 (Src homology 2-
containing tyrosine phosphatase) gene leads to severe immune dysfunction in mice (11). 
T lymphocytes with a mutated CD45 (Protein tyrosine phosphatase, receptor type, C) 
gene are irresponsive to stimulation by antigen and it might be related to autoimmune 
diseases (12). PTP1B and PTPα function as negative regulators of insulin signaling and 
they are involved in Type II diabetes and obesity (13). 
 
Figure 1.7. HCPTP levels are elevated in transformed cell lines. (10) Detergent lysates 
from various cell lines were probed for HCPTP. Oncogene-transformed cells (MCF7, SK-
BR-3, MDA-MB-435, and MDA-MB-231) overexpress HCPTP compared to non-
transformed cells (MCF-10AneoST denoted as NeoST). Image reproduced with 





Table 1. Overview of PTPs that are potential therapeutic targets (12). Image modified 
from Rob Hooft van Huijsduijnen et al. 2002. 


































Interest in PTPs began to rise because PTPs play critical roles in the regulation 
of various cellular signaling pathways and they emerged as potential drug targets for 
several disease areas in Table 1 (14). Designing specific PTP inhibitors will ultimately 
function as potential therapeutic agents to treat various diseases including cancer, 
obesity, and autoimmune diseases. 
However, developing rational PTP inhibitors for therapeutic treatment is considered to be 
a challenging task. First, because a large number of PTPs have the consensus 
sequence CX5R, which forms the active site, it seems improbable that specifically 
designed inhibitors would selectively target only one PTP. Second, PTP inhibition may 
lead to unwanted side-effects because a key signaling pathway may be regulated by 
various PTPs or a single PTP may regulate diverse cellular signaling pathways.  
The following experiments were performed to understand the key residues of 
HCPTP-A and HCPTP-B for substrate binding and activity and help answer major 
concerns in designing of rational PTP inhibitors.  
 Two low molecular weight PTP isoenzymes, HCPTP-A and HCPTP-B, are 
generally expressed in human. These two enzymes, HCPTP-A and B have highly 
identical sequences except for the variable loop (residues 40 - 73) region, which 
determines its binding substrates leading either to an inhibitor or activator response. 
Based on the preliminary study, using biochemical substrates and inhibitors as well as 
analyzing the structure, our lab identified with three potential variable loop residues (49, 
50, and 53) that may influence the determination of catalytic efficiency and substrate 
binding for HCPTP-A and -B. Thus, a major goal of this project is investigating the effect 
of these residues on HCPTP-A and -B activity through site-directed mutations of 
residues 49, 50, and 53. This will provide a more detailed understanding of specific 
residues that control the affinity of substrates for the PTPs. Moreover, understanding 
which residue plays a critical role in substrate binding and activity for HCPTP-A and -B 
may yield an advance in understanding the biological roles of PTPs as well as 







CHAPTER 2. CLONING, EXPRESSION, AND PURIFICATION OF THE HCPTP-A AND  






Two low molecular weight PTP isoenzymes, HCPTP-A and HCPTP-B, are 
soluble proteins with molecular mass of approximately 18 kDa. HCPTP-A and -B consist 
of single polypeptide chains of 157 amino acids and have universal PTPase consensus 
sequence CX5R that forms the active site P loop. The only distinct sequence between 
HCPTP-A and HCPTP-B consists of residues 40-73 which forms the variable loop (8). 
Despite HCPTP-A and -B showing a structurally similar active site including the universal 
PTPase consensus sequence, they show different activity against inhibitors and 
phosphotyrosine peptides (7). Moreover, it was recently shown that HCPTP-A and -B 
preferentially dephosphorylate different phosphotyrosine sites related to control of 
EphA2 activity and downstream signaling pathways. HCPTP-A preferentially 
dephosphorylates tyrosine Y772 of the kinase domain in the activation loop, while 
HCPTP-B preferentially dephosphorylates the SAM domain tyrosine, Y960. (9) However, 
which residues of HCPTP-A and -B are responsible for different activity toward 
phosphotyrosine sites of EphA2 still remains unknown.   
  Based on the preliminary study, our lab identified three potential variable loop 
residues (49, 50, and 53) that may influence the determination of enzymatic activity and 
substrate binding for HCPTP-A and -B. Residue 49, which is Tyr(Y) in HCPTP-A and 
Trp(W) in HCPTP-B, located above the active site forming the hydrophobic sandwich 
with residues Tyr-131 and -132, affects interaction of the ring portion of phosphotyrosine 
substrates. Residues 50 and 53 contribute to the difference of the variable loops charge 
distribution. Glu(E)-50 in HCPTP-A, contains a negatively charged side chain, whereas, 




50 and 53, are important for the interaction of enzymes and substrates recognized by 
their charge distribution. Thus, investigating the effect of these residues on HCPTP-A 
and -B activity through site-directed mutations of residues 49, 50, and 53 will provide a 
more detailed understanding of specific residues that control the affinity of substrates to 














































2.2.1. Cloning HCPTP-A and -B, Single, Double, and Triple Mutants 
 
 Our lab already has vector pET11d containing the plasmid of HCPTP-A, A-Y49W, 
E50N, N53R, A-Y49W/E50N and HCPTP-B, B-W49Y, N50E, R53N, B-W49Y/N50E, 
respectively. These plasmids were used as templates for the polymerase chain reaction 
(PCR) to yield other types of double and triple mutants via site-directed mutagenesis. 
Site-directed mutagenesis was carried out to make HCPTP-A E50N/N53R using 
pET11d vector containing HCPTP-A E50N template DNA with forward and reverse 
primers: 5’ - CAA CTT CCG GGT ATA ACA TAG GGC GCC CCC CTG - 3’ and 5’ - 
CAG GGG GGC GCC CTA TGT TAT ACC CGG AAG TTG - 3’, respectively. HCPTP-A 
Y49W/N53R was yielded from pET11d::HCPTP-A Y49W template plasmid using the 
following forward primers 5’ - CAA CTT CCG GGT GGG AGA TAG GGC GCC - 3’ and 
reverse primers 5’ - GGC GCC CTA TCT CCC ACC CGG AAG TTG - 3’.To create 
HCPTP-A Y49W/E50N/N53R, site-directed mutagenesis was performed using HCPTP-A 
Y49W/E50N as template plasmid with forward and reverse primers: 5’ - CTT CCG GGT 
GGA ACA TAG GGC GAC CCC CTG ACT ACC - 3’ and 5 ’- GGT AGT CAG GGG GTC 
GCC CTA TGT TCC ACC CGG AAG - 3’.  
HCPTP-B N50E/R53N was PCR amplified from pET11d::HCPTP-B N50E template with 
forward primers 5’ - CTG TTT CTG ACT GGG AGG TGG GCA ACT CCC CAG - 3’ and 
reverse 5’ - CTG GGG AGT TGC CCA CCT CCC AGT CAG AAA CAG - 3’. In order to 
yield HCPTP-B W49Y/R53N, HCPTP-B W49Y was used as template DNA for site-
directed mutagenesis with forward and reverse primers: 5’ - GCG GTG CTG TTT CTG 
ACT ATA ACG TGG GCA ACT CCC CAG - 3’ and 5’ - CTG GGG AGT TGC CCA CGT 
TAT AGT CAG AAA CAG CAC CGC - 3’. HCPTP-B W49Y/N50E/R53N was created 
from pET11d::HCPTP-B W49Y/N50E using site-directed mutagenesis with forward 
primers 5’ - GTT TCT GAC TAT GAG GTG GGC AAC TCC CCA GAC CCA AGA GCT 
GTG - 3’ and reverse primers 5’ - CAC AGC TCT TGG GTC TGG GGA GTT GCC CAC 
CTC ATA GTC AGA AAC - 3’, respectively (Table 2 - Table 3). 
The PCR sample contained 1 ul of 10 uM forward and reverse primer, 1 ul 




Phusion DNA polymerase, and 11.8 ul nuclease free water. 20 cycles of PCR were 
performed for 50 seconds at 98°C for denaturation, 50 seconds at 60°C for annealing, 
and 6 minutes 30 seconds at 72°C for elongation (Figure 2.1.).  Following the reaction, 
the PCR product was digested with DpnI to cleave methylated sites of the template 
plasmid but not the PCR product.  
The 4 ul of PCR product were transformed into 20 ul E.coli XL-1 Blue competent 
cells each for 45 minutes on ice. The mixture was heat shocked at 42°C for 40 - 45 
seconds and allowed to recover on ice for 5 minutes, at which point 500 ul of Luria broth 
(LB) media was added to the sample. That was then placed in the incubator at 37°C for 
45 minutes, 220 rpm. 200 ul of the sample was spread on a Luria agar plate containing 
50 ug/ml ampicilin and allowed to incubate overnight at 37°C. LB media is made by 
dissolving 10 g NaCl, 10 g tryptone, and 5 g yeast extract in 1000 mL deionized water, 
which is then autoclaved. 
Colonies was selected from each transformation and used to inoculate 10 mL overnight 
cultures, that were subsequently pelleted. Plasmid DNA was isolated from the pellets 
using a Qiagen miniprep kit. Each sample was then sent for sequencing to confirm the 
















Figure 2.1. Site-directed mutagenesis for HCPTP-A E50N/N53R, Y49W/N53R, 
Y49W/E50N/N53R, and HCPTP-B N50E/R53N, W49Y/R53N, W49Y/N50E/R53N. 
HCPTP-A E50N, Y49W, Y49W/E50N and HCPTP-B W49Y, N50E, W49Y/N50E 
plasmids were used as templates for the polymerase chain reaction (PCR) to yield other 
types of double and triple mutants via site-directed mutagenesis. 20 cycles of PCR were 
performed for 50 seconds at 98°C, 50 seconds at 60°C, and 6 minutes 30 seconds at 





































2.2.2. Expression and Purification of HCTPT-A and -B Wild Type, Single, Double, and 
Triple Mutants 
 
 E.coli BL21 competent cells were transformed with pET11d::HCPTP-A or 
pET11d::HCPTP-A single mutants (Y49W or E50N or N53R) or pET11d::HCPTP-A 
double mutants (Y49W/E50N, E50N/N53R, Y49W/N53R) or pET11d::HCPTP-A triple 
mutants (Y49W/E50N/N53R). Also, pET11d::HCPTP-B or pET11d::HCPTP-B single 
mutants (W49Y or N50E or R53N) or pET11d::HCPTP-B double mutants (W49Y/N50E 
or N50E/R53N or W49Y/R53N) or pET11d::HCPTP-B triple mutants (W49Y/N50E/R53N) 
were transformed into E.coli BL21 competent cells. Single colonies from each 
transformation were inoculated in 10 mL LB cultures containing 50 ug/ml ampicilin and 
allowed to grow overnight at 37°C. Overnight 10 mL cultures were used to inoculate 
flasks containing 1 L LB media, 50 ug/ml ampicilin. LB media is made by dissolving 10 g 
NaCl, 10 g tryptone, and 5 g yeast extract in 1000 mL deionized water, which is then 
autoclaved.  Cultures were grown at 37°C until an O.D.600 = 0.6 - 0.8 reach. At this 
point, protein expression was induced by addition of 0.4 mM Isopropyl β-d-1-
thiogalactopyranoside (IPTG) in 1 L LB cultures. Cultures were incubated for an 
additional 16 - 18 hours at 16°C and then, cells were pelleted at 5000 g, 4°C, and then 
frozen at -20°C. 
 Frozen cell pellets were resuspended with buffer A that contains 10 mM sodium 
acetate, 10 mM NaH2PO4 and 50 mM NaCl, and 1 mM EDTA at pH 4.8 after which 30ul 
Dithiothreitol (DTT) and 30ul Phenylmethanesulfonylfluoride (PMSF) were added. The 
resuspended cells were lysed by three or four passage through a French Press at 1500 
psi, after which 100 ul of 100x Halt Protease Inhibitor Cocktali from Thermo Scientific 
was added. Cell lysates were pelleted at 20,000 rpm for 25 minutes at 4°C. 
 The supernatants of cell lysate were loaded onto a 20 mL HiPrep 16/10 SP 
cation exchange column which was pre-equilibrated with buffer A and attached to an 
AKTA Prime liquid chromatography system. The protein was eluted with a buffer B 
consisting of 300 mM NaH2PO4, 1 mM EDTA at pH 5.1 and baseline was set up 
according to the protein absorbance at 280 nm. Aliquots from 10 mL fractions collected 
through the cation exchange chromatography system were analyzed by SDS-PAGE 
using 15% gels. Fractions including only purified protein were combined and 




4°C. Concentrated protein was loaded over a HiPrep 26/60 Sephacryl S-200 size 
exclusion column which was pre-equilibrated with a buffer A’ consisting of 100mM 
sodium acetate, 10 M EDTA at pH 4.8. Aliquots from10 mL fractions were analyzed by 
SDS-PAGE 15% gels. Fractions containing only HCPTP were combined and then 
concentrated to approximately 1.5 - 2 mL through a 10kDa cutoff spin concentrator at 
4500 g and 4°C. Concentrated protein containing HCPTP-A and -B, single mutant, 










































2.3.1. Purification of HCPTP-A and -B, Single, Double, and Triple mutant 
 
The HCPTP-A and -B, single mutant (A-Y49W, E50N, N53R and B-W49Y, N50E, 
R53N), double mutant (A-Y49W/E50N, E50N/N53R, Y49W/N53R and B-W49Y/N50E, 
N50E/R53N, W49Y/R53N), and triple mutant (A-Y49W/E50N/N53R and B-
W49Y/N50E/R53N) were cloned into pET11d expression vectors and transformed into 
E.coli BL21 competent cells. The induced cultures were lysed by passage through a 
French Press at 1500 psi and pelleted. Large-scale expression of wild-type and mutant 
forms of HCPTP-A and -B was followed by a two-step purification involving ion-
exchange and size-exclusion chromatography.  
The supernatants of cell lysate were purified initially by a HiPrep 16/10 SP cation 
exchange column as seen in Figure 2.2. - 2.5. Eluted HCPTP-A and -B, single mutant, 
double mutant, and triple mutant was concentrated and purified again via HiPrep 26/60 
Sephacryl S-200 size exclusion choromatography system as seen in Figure 2.6. - 2.9.  
The purified protein was concentrated to between 1.5 - 2 mL, which resulted in a 
HCPTP-A WT concentration of 2.06 mg/ml, A-Y49W concentration of 1.29 mg/ml, A-
E50N concentration of 2.33 mg/ml, A-N53R concentration of 1.67 mg/ml, A-Y49W/E50N 
concentration of 2.05 mg/ml, A-E50N/N53R concentration of 2.2 mg/ml,  A-Y49W/N53R 
concentration of 1.99 mg/ml, A-Y49W/E50N/N53R concentration of 1.63 mg/ml, and in a 
HCPTP-B WT concentration of 1.73 mg/ml, B-W49Y concentration of 1.71 mg/ml, B-
N50E concentration of 1.99 mg/ml, B-R53N concentration of 1.57 mg/ml, B-W49Y/N50E 
concentration of 1.82 mg/ml, B-N50E/R53N concentration of1.69 mg/ml, B-W49Y/R53N 
concentration of 2.19 mg/ml, B-W49Y/N50E/R53N concentration of 1.34 mg/ml, 
respectively. Aliquots of purified HCPTP-A and -B, single, double, and triple mutants 
were analyzed for purity using SDS-PAGE on a 15% gel as seen in Figure 2.10 - 2.11. 
Because the molecular weights of HCPTP-A and HCPTP-B are approximately 18 kDa, 
HCPTP-A and -B, single, double and triple mutants migrated at molecular weight 




single, double, triple mutants were used for p-Nitrophenyl Phosphate (pNPP) assay for 





































Figure 2.2. Primary purification of HCPTP-A and HCPTP-A Y49W/E50N/N53R using 
cation exchange chromatography. The supernatants of cell lysate were loaded onto a 
HiPrep 16/10 SP cation exchange column. Once a baseline was established at 280 nm, 
protein was eluted off the column and collected in 10 mL fractions. Green lines indicate 
the shift from 10 mM sodium acetate, 10 mM NaH2PO4 and 50 mM NaCl, and 1 mM 
EDTA at pH 4.8 to 300 mM NaH2PO4, 1 mM EDTA at pH 5.1. Blue lines indicate the 
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Figure 2.4. Primary purification of HCPTP-B and HCPTP-B W49Y/N50E/R53N using 
cation exchange chromatography. The supernatants of cell lysate were loaded onto a 
HiPrep 16/10 SP cation exchange column. Once a baseline was established at 280 nm, 
protein was eluted off the column and collected in 10 mL fractions. Green lines indicate 
the shift from 10 mM sodium acetate, 10 mM NaH2PO4 and 50 mM NaCl, and 1 mM 
EDTA at pH 4.8 to 300 mM NaH2PO4, 1 mM EDTA at pH 5.1. Blue lines indicate the 
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Figure 2.6. Secondary purification of HCPTP-A and HCPTP-A Y49W/E50N/N53R via 
size exclusion chromatography. The supernatants of cell lysate were loaded onto a 
HiPrep 26/10 SP Sephacryl S-200 size exclusion column. The protein was eluted off the 
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Figure 2.8. Secondary purification of HCPTP-B and HCPTP-B W49Y/N50E/R53N via 
size exclusion chromatography. The supernatants of cell lysate were loaded onto a 
HiPrep 26/10 SP Sephacryl S-200 size exclusion column. The protein was eluted off the 
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Figure 2.10. SDS-PAGE gel of purified HCPTP-A, A-Y49W, E50N, N53R, Y49W/E50N, 
E50N/N53R, Y49W/N53R, Y49W/E50N/N53R. 6 ug of each sample were loaded. Lane 1 







Figure 2.11. SDS-PAGE gel of purified HCPTP-B, B-W49Y, N50E, R53N, W49Y/N50E, 
N50E/R53N, W49Y/R53N, W49Y/N50E/R53N. 6 ug of each sample were loaded. Lane 1 







CHAPTER 3. ACTIVITY TEST OF HCPTP-A AND -B, SINGLE, DOUBLE, AND TRIPLE 





Site-directed mutagenesis was used to examine the role of residues 49, 50, and 
53 involved in forming the variable loop of HCPTP-A and -B. Both Glu(E)-50 and Asn(N)-
53 in HCPTP-A were mutated to Asn(N)-50 and Arg(R)-53. Tyr(Y)-49 and Asn(N)-53 of 
HCPTP-A were replaced by Trp(W)-49 and Arg(R)-53. For triple mutant (A-
Y49W/E50N/N53R), all three residues, Tyr(Y)-49, Glu(E)-50, and Asn(N)-53, were 
mutated to Trp(W)-49, Asn(N)-50, and Arg(R)-53 via site-directed mutagenesis. In 
HCPTP-B N50E /R53N, Asn(N)-50 and Arg(R)-53 were replaced by Glu(E)-50 and 
Asn(N)-53. Both Trp(W)-49 and Arg(R)-53 in HCPTP-B were mutated to Tyr(Y)-49 and 
Asn(N)-53. In triple mutant (B- W49Y/N50E/R53N), Trp(W)-49, Asn(N)-50 and Arg(R)-53 
were replaced by Tyr(Y)-49, Glu(E)-50 and Asn(N)-53.  
 Protein tyrosine phosphatases are defined by their ability to hydrolyze the 
phosphate group from phosphotyrosine. The enzymatic activity of HCPTP-A, Y49W, 
E50N, N53R, Y49W/E50N, E50N/N53R, Y49W/N53R, Y49W/E50N/N53R, and HCPTP-
B, W49Y, N50E, R53N, W49Y/N50E, N50E/R53N, W49Y/R53N, W49Y/N50E/R53N is 
examined by measuring dephosphorylation of the chromogenic substrate p-Nitrophenyl 













3.2.1. p-Nitrophenyl Phosphate Assay (pNPP) Test 
 
The enzymatic assays of all HCPTP-A and -B, single, double, and triple mutants 
were performed at room temperature (21 - 25°C) in 100 mM sodium acetate, 10 mM 
EDTA, pH 5.0. Each enzyme sample with p-Nitrophenyl Phosphate (pNPP) in a 1 cm 
quartz cuvette was monitored using an Ultrospec 3100 pro spectrometer. The reaction 
was initiated by adding 10 ul of 0.5 uM enzyme with 10 ul pNPP (0.1 to 5 Km) in a 180 ul 
reaction buffer. The initial velocities were measured by determining the release of p-
nitrophenolate in a colorimetric procedure with a wavelength of 405 nm and taking the 
range 0.05 - 1 of absorbance. 
For Vmax and Km measurements, eight different pNPP substrate concentrations (0.1 to 5 
Km) were used and enzyme activity was calculated from the Beer-Lambert Law. The 
triplicate measurements were made with an extinction coefficient of 1.78 x 104 M-1•cm-1 
for the standard Michaelis-Menten equation. The values were fitted to the Michaelis-






















3.3. Data and Results 
 
Vmax, Km (Michaelis constant), Kcat (catalytic rate constant), and Kcat/Km values for 
pNPP were determined at pH 5.0 and at room temperature for the HCPTP-A WT, single 
(Y49W, E50N, N53R), double (Y49W/E50N, E50N/N53R, Y49W/N53R), triple mutant 
(Y49W/E50N/N53R), and HCPTP-B WT, single (W49Y, N50E, R53N), double 
(W49Y/N50E, N50E/R53N, W49Y/R53N), triple mutant (W49Y/N50E/R53N). The kinetic 
data are summarized in Table 4 and Figure 2.12 - 13.  
 With the substrates pNPP, Km values for HCPTP-A, Y49W, E50N, N53R, 
Y49W/E50N, E50N/N53R, Y49W/N53R, Y49W/E50N/N53R were 0.22, 0.10, 0.78, 0.10, 
0.15, 0.20, 1.44, 0.17 mM, and for HCPTP-B, W49Y, N50E, R53N, W49Y/N50E, 
N50E/R53N, W49Y/R53N, W49Y/N50E/R53N were 0.66, 0.27, 0.44, 0.34, 0.33, 0.26, 
1.01, 0.21 mM, respectively.  
Except for A-E50N and A-Y49W/N53R, all of HCPTP-A single, double, and triple 
mutants showed Km values that were similar to or less than HCPTP-A wild type. The 
most striking results were seen for A-E50N, A-Y49W/N53R. The A-E50N and A-
Y49W/N53R exhibited 3.5- and 6.5-fold increased Km values, 0.78 mM and 1.44 mM, 
compared to the Km for HCPTP-A of 0.22 mM. Moreover, the Km for A-E50N (0.78 mM) 
was more similar to the Km value for HCPTP-B (0.66 mM) than to HCPTP-A (0.22 mM). 
Interestingly, except for B-W49Y/R53N which showed an increased Km value, all 
HCPTP-B single, double, and triple mutants showed decreased Km values compared to 
the HCPTP-B and these decreased Km for HCPTP-B mutants were similar to the Km for 
HCPTP-A. The Km values for the mutants indicate that the binding interaction of B-W49Y, 
N50E, R53N, W49Y/N50E, N50E/R53N, W49Y/N50E/R53N may be more similar to the 
binding interaction of HCPTP-A than to that of the HCPTP-B.  
 The ratio Kcat/Km shows the catalytic efficiency of enzymes including wild type, 
single, double, and triple mutant for pNPP substrate. The Kcat/Km values for HCPTP-A 
and HCPTP-B were 0.78 and 0.27 s-1 mM-1, respectively.  
Interestingly, all HCPTP-A mutants, A-Y49W, E50N, N53R, Y49W/E50N, 
E50N/N53R, Y49W/N53R, Y49W/E50N/N53R, showed decreased Kcat/Km compared to 
the HCPTP-A wild type.  Moreover, the Kcat/Km value for HCPTP-A Y49W/E50N/N53R is 
highly decreased compared to the Kcat/Km values for single and double mutants. The 




HCPTP-A Y49W/E50N/N53R  is more like HCPTP-B (0.27 s-1 mM-1) than HCPTP-A 
(0.78 s-1 mM-1).  
Thus, the decreased Kcat/Km values for HCPTP-A Y49W, E50N, N53R, Y49W/E50N, 
E50N/N53R, Y49W/N53R, especially Y49W/E50N/N53R, compared to HCPTP-A 
indicate these three mutated residues, Trp(W), Asn(N), and Arg(R) which originated from 
HCPTP-B, reduce the enzyme efficiency of HCPTP-A. 
On the other hand, all HCPTP-B mutants, B-W49Y, N50E, R53N, W49Y/N50E, 
N50E/R53N, W49Y/R53N, W49Y/N50E/R53N exhibited increased Kcat/Km values 
compared to the HCPTP-B wild type. The most striking results were seen for B-W49Y 
and B-N50E. The B-W49Y and B-N50E showed 3- and 2.5-fold increased Kcat/Km values 
( 0.86  and 0.71 -1 mM-1) compared to the Kcat/Km for HCPTP-B (0.27 -1 mM-1). Moreover, 
Kcat/Km values for B-W49Y (0.86 -1 mM-1) and B-N50E (0.71 -1 mM-1) were more similar to 
Kcat/Km for HCPTP-A (0.78 -1 mM-1) than to HCPTP-B (0.27 -1 mM-1).  
Thus, the increased Kcat/Km values for HCPTP-B R53N, W49Y/N50E, N50E/R53N, 
W49Y/R53N, W49Y/N50E/R53N, especially W49Y and N50E, over HCPTP-B suggest 






















Figure 2.12. Kcat/Km values for HCPTP-A and -B, A-Y49W, E50N, N53R, A-Y49W/E50N, 
E50N/N53R, Y49W/N53R, A-Y49W/E50N/N53R, respectively.  
 
 
Figure 2.13. Kcat/Km values for HCPTP-A and -B, B-W49Y, N50E, R53N, B-W49Y/N50E, 


















Interest in Protein Tyrosine Phosphatases (PTPs) began to rise because PTPs 
play important roles in the regulation of many cellular signaling pathways including 
cellular growth, differentiation and metabolism and PTPs emerged as potential drug 
targets for several disease areas including obesity, cancer, autoimmune and infectious 
diseases (14) in Table 1.  
EphA2 is a receptor tyrosine kinase which is hypo-phosphorylated and 
overexpressed in many metastatic cancers. The level of phosphorylation of EphA2 is 
controlled by the human cytoplasmic protein tyrosine phosphatase (HCPTP), which is 
also overexpressed in cancers (10). This result indicates that HCPTP has oncogenic 
potential and seems to be responsible for metastatic transformation. Designing specific 
PTPs inhibitors will ultimately function as potential therapeutic drugs to treat various 
diseases which are related to deregulation of PTPs.  
  HCPTP-A and -B are soluble proteins which consist of single polypeptide chains 
of 157 amino acids and have the PTPase consensus sequence (CX5R) which forms the 
active site P loop. The only different sequence between HCPTP-A and -B is an mRNA 
splice variant sequence including amino acids 40 - 73 which forms the variable loop (8). 
HCPTP-A and HCPTP-B show different activity towards inhibitors and phosphotyrosine 
peptides (7). HCPTP-A has a higher activity towards phosphotyrosine, p-nitrophenyl 
phosphate (pNPP) and inhibitors, while HCPTP-B shows a lower response to pNPP and 
phosphotyrosine as well as inhibitors. Moreover, HCPTP-A and HCPTP-B 
dephosphorylate different phosphotyrosine sites related to control of EphA2 activity and 
downstream signaling pathways (9).  
Based on the preliminary study, our lab identified three potential variable loop 
residues (49, 50, and 53) which may influence substrate binding and catalytic efficiency 
of HCPTP-A and -B (7). The first one is Tyr(Y)-49 in HCPTP-A and Trp(W)-49 in 
HCPTP-B, located above the active site forming the hydrophobic sandwich with Tyr(Y)-
131 and -132, which affects interaction of the phosphotyrosine substrates. The second is 
Glu(E)-50 in HCPTP-A, which contains a negatively charged side chain, whereas, 
Arg(R)-53 in HCPTP-B, possesses a positively charged side chain. These two residues, 
50 and 53, play critical roles in the interaction of enzymes and substrates recognized by 




With the substrate pNPP, HCPTP-A (0.22 mM) showed 3-fold decreased Km 
value compared to the Km for HCPTP-B (0.66 mM). Because the Km is dissociation 
constant, this result suggests that HCPTP-A binds three times more tightly to pNPP than 
HCPTP-B. On the other hand, Kcat/Km value, the catalytic efficiency towards pNPP 
substrate, for HCPTP-A (0.78 s-1 mM-1) increased approximately 3-times compared to 
the Kcat/Km for HCPTP-B (0.27 s-1 mM-1) even though Kcat value for HCPTP-A and -B 
were similar to each other (0.17 s-1 and 0.18 s-1). Thus, these data indicate that HCPTP-
A has more efficient enzymatic and catalytic activity towards pNPP than HCPTP-B.    
Except for A-E50N and A-Y49W/N53R, all HCPTP-A single, double, and triple 
mutants showed Km values which were similar to or less than HCPTP-A WT. These 
results were unexpected. Interestingly, Kcat values for all HCPTP-A single, double, and 
triple mutants is highly decreased compared to HCPTP-A WT, but A-E50N and A-
Y49W/N53R. Thus, three residues, Trp(W), Asn(N), and Arg(R) which originated from 
HCPTP-B, are more likely affect on enzyme turn-over number (Kcat) than enzyme affinity 
toward substrate.   
On the other hand, except for B-W49Y/R53N, all HCPTP-B single, double, and triple 
mutants showed 2- and 3-times decreased Km values in comparison to HCPTP-B. These 
decreased Km for HCPTP-B single, double, and triple mutants were similar to the Km 
value for HCPTP-A, which suggests that the binding interaction of B-W49Y, N50E, R53N, 
W49Y/N50E, N50E/R53N, W49Y/N50E/R53N may be more similar to the binding 
interaction of HCPTP-A than to that of HCPTP-B. Thus, mutated three residues, Tyr(Y), 
Glu(E), and Asn(N) which derived from HCPTP-A, seems to enhance binding interaction 
of HCPTP-B for pNPP substrate.  
Interestingly, all HCPTP-A single (Y49W, E50N, N53R), double (Y49W/E50N, 
E50N/N53R, Y49W/N53R), and triple mutant (Y49W/E50N/N53R) showed decreased 
Kcat/Km values in comparison to HCPTP-A WT. The most striking results were seen for 
A-Y49W/E50N/N53R. The Kcat/Km value for A-Y49W/E50N/N53R is 1.6-fold decreased 
than HCPTP-A WT. The HCPTP-A Y49W/E50N/N53R shows Kcat/Km value (0.48 s-1 mM-
1) more like HCPTP-B (0.27 s-1 mM-1) than HCPTP-A (0.78 s-1 mM-1). The decreased 
Kcat/Km values for HCPTP-A single mutants (Y49W, E50N, N53R), double mutants 
(Y49W/E50N, E50N/N53R, Y49W/N53R), and especially triple mutant 




residues, Trp(W), Asn(N), and Arg(R) which originated from HCPTP-B WT, seems to 
affect enzymatic activity and especially reduce catalytic efficiency for HCPTP-A. 
All HCPTP-B single (W49Y, N50E, R53N), double (W49Y/N50E, N50E/R53N, 
W49Y/R53N), and triple mutant (W49Y/N50E/R53N) showed increased Kcat/Km values 
over the HCPTP-B WT. Especially, B-W49Y and B-N50E showed 3- and 2.5-fold 
increased Kcat/Km values (0.86 and 0.71 s-1 mM-1) compared to the Kcat/Km for HCPTP-B 
(0.27 s-1 mM-1). These increased Kcat/Km for B-W49Y (0.86 s-1 mM-1) and B-N50E (0.71 s-
1 mM-1) were more similar to the Kcat/Km value for HCPTP-A (0.78 s-1 mM-1) than to 
HCPTP-B (0.27 s-1 mM-1). Moreover, the Kcat/Km for HCPTP-B triple mutant (0.53 s-1 mM-
1) was also more similar to HCPTP-A (0.78 s-1 mM-1) than to HCPTP-B (0.27 s-1 mM-1).                     
The increased Kcat/Km for HCPTP-B R53N, double (W49Y/N50E, N50E/R53N, 
W49Y/R53N), and triple mutant (W49Y/N50E/R53N), especially W49Yand N50E 
compared to HCPTP-B WT indicates that the three mutated residues, Tyr(Y), Glu(E), 
and Asn(N) that originated from HCPTP-A, seems to improve catalytic efficiency and 
enzyme activity of HCPTP-B. 
 Taken together, these results are consistent with the hypothesis that the three 
variable loop residues (Tyr(Y)-49, Glu(E)-50, Asn(N)-53 in HCPTP-A and Trp(W)-49, 
Asn(N)-50, Arg(R)-53 in HCPTP-B) are the key residues affecting the substrate binding 
for HCPTP-A and HCPTP-B and these three residues play a significant role in enzymatic 
activity.  
For a better investigation of the effect of three potential variable loop residues 
(positions 49, 50, and 53) of HCPTP-A and HCPTP-B, additional research including 
Malachite Green Assay with phosphotyrosine peptides (derived from the EphA2) at 
physiological conditions (pH 7 and 37°C) is needed as pNPP substrate is a synthetic 
molecule of smaller size which can easily enter and leave active site of enzyme.  
Using biological substrate such as phosphotyrosine peptides originated from the EphA2 
will provide a more detailed understanding of the physiological function of HCTPT-A and 
HCPTP-B. In addition, future research measuring the dissociation constant (Ki), with 
inhibitors will also provide characteristics of specific residues that control the affinity of 
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